Catalyst
Slingshot members are tracking this event:
Enrollment for ALXN-1210 Phase 3 pediatric study on atypical hemolytic uremic syndrome (aHUS) to initiate in second quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALXN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 27, 2017
Occurred Source:
http://news.alexionpharma.com/press-release/financial-news/alexion-reports-second-quarter-2017-results
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Atypical Hemolytic Uremic Syndrome (ahus), Alxn1210, Phase 3 Study
